Science
Waisman Biomanufacturing partners with GigaGen to manufacture new COVID-19 drug – Mirage News
Waisman Biomanufacturing at the University of Wisconsin-Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by…
Waisman Biomanufacturing at the University of Wisconsin-Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by California-based biotech company GigaGen.
The drug, called GIGA-2050, uses a new approach similar to treating COVID-19 patients with convalescent plasma, or blood products from people recovering (convalescing) from an infection. Waisman Biomanufacturing was created to facilitate just this sort of development and testing of new types of drugs.
“Our miss…
-
Noosa News24 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation
-
General23 hours agoPort’s lease a ‘mistake’ as major parties flag takeover
-
Business22 hours agoThese ASX 200 shares could rise 50% to 60%
-
General21 hours agoAustralia’s Myanmar community mourns earthquake losses